Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM1A | O60341 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694153 | 0.85 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL4066082 | 0.85 | MGLL (0.65) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3693014 | 0.83 | POLB (0.58) | POLBTP53MAPTKDM1AMAOA | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.83 | POLB (0.78) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL1160238 | 0.82 | POLB (0.64) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10366198 | 0.82 | POLB (0.64) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL15777029 | 0.82 | TP53 (0.67) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL1171853 | 0.82 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL1870929 | 0.82 | POLB (0.71) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL12348789 | 0.81 | RAB9A (0.65) | POLBTP53MAPTKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-114075139-A | Five-membered heteroaromatic ring compound and application thereof in medicines | 广东东阳光药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-2459553-B1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| EP-2459553-B1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| EP-2459553-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | Basilea Pharmaceutica AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012577-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012577-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | POLB 3074/4885TP53 837/4885MAPT 3263/4885 |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | SSB, VHL, AHR | POLB 1876/4885TP53 303/4885MAPT 4882/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | POLB 3074/4885TP53 837/4885MAPT 3263/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | POLB 3074/4885TP53 837/4885MAPT 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.